Comparison of blocker impact on RIV for all HBE monolayers
| Drug order | Basal | Forskolin | GlyH-101 | Forskolin+GlyH-101 | Forskolin+Glibenclamide | GlyH-101+Forskolin | Glibenclamide+Forskolin |
| wtHBE | 1.06 ± 0.01 | 1.06 ± 0.02 | 0.97 ± 0.01 | 0.83 ± 0.03 | 1.39 ± 0.14 | 0.89 ± 0.01 | 1.50 ± 0.03 |
| GP adjusteda | 1.17 ± 0.06 | 0.90 ± 0.05 | 0.66 ± 0.03 |
| Drug order | Basal | Forskolin | GlyH-101 | Forskolin+GlyH-101 | Forskolin+Glibenclamide | GlyH-101+Forskolin | Glibenclamide+Forskolin |
| wtHBE | 1.06 ± 0.01 | 1.06 ± 0.02 | 0.97 ± 0.01 | 0.83 ± 0.03 | 1.39 ± 0.14 | 0.89 ± 0.01 | 1.50 ± 0.03 |
| GP adjusteda | 1.17 ± 0.06 | 0.90 ± 0.05 | 0.66 ± 0.03 |
Order of agonist or blocker represents experimental additions. Each measurement represents an n ≥ 6.
Values calculated with correction for paracellular conductance.